Last reviewed · How we verify
endostar+chemoradiotherapy
Endostar is a recombinant human endostatin that inhibits angiogenesis by blocking new blood vessel formation in tumors, used in combination with chemotherapy and radiotherapy to enhance anti-tumor effects.
Endostar is a recombinant human endostatin that inhibits angiogenesis by blocking new blood vessel formation in tumors, used in combination with chemotherapy and radiotherapy to enhance anti-tumor effects. Used for Non-small cell lung cancer (in combination with chemotherapy and/or radiotherapy), Various solid tumors (as adjunctive therapy with chemoradiotherapy).
At a glance
| Generic name | endostar+chemoradiotherapy |
|---|---|
| Sponsor | Second Affiliated Hospital of Xi'an Jiaotong University |
| Drug class | Angiogenesis inhibitor |
| Target | Endothelial cells; inhibits multiple angiogenic pathways |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Endostar (rh-endostatin) is an angiogenesis inhibitor derived from the C-terminal fragment of collagen XVIII. It suppresses tumor neovascularization by inhibiting endothelial cell proliferation and migration, thereby reducing blood supply to tumors. When combined with chemoradiotherapy, it works synergistically to enhance cytotoxic effects and improve treatment outcomes.
Approved indications
- Non-small cell lung cancer (in combination with chemotherapy and/or radiotherapy)
- Various solid tumors (as adjunctive therapy with chemoradiotherapy)
Common side effects
- Hematologic toxicity (anemia, leukopenia, thrombocytopenia)
- Gastrointestinal toxicity
- Fatigue
- Injection site reactions
- Radiation-related toxicity (enhanced by combination)
Key clinical trials
- Endostar Combined With Concurrent Chemoradiotherapy For Locally Advanced Cervical Carcinoma (PHASE2)
- Envafolimab Combined With Endostar and Concurrent Chemoradiotherapy for Locally Advanced Primary Cervical Cancer
- Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma (PHASE2)
- Rh-Endostatin Combined With CCRT(50 Gy) Followed by Durvalumab Maintenance for the Treatment of Specific Phase III NSCLC (PHASE4)
- Study of Endostar Combined With TP Regimen for Esophageal Cancer (PHASE4)
- Endostar Combined With Concurrent Radiochemotherapy for Treatment of Unresectable Stage III NSCLC
- CCRT Combined With Endostar for the Treatment of Locally Advanced Cervical Cancer (PHASE2)
- Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |